![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CSTF1 |
Gene summary for CSTF1 |
![]() |
Gene information | Species | Human | Gene symbol | CSTF1 | Gene ID | 1477 |
Gene name | cleavage stimulation factor subunit 1 | |
Gene Alias | CstF-50 | |
Cytomap | 20q13.2-q13.31 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q05048 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1477 | CSTF1 | GSM4909285 | Human | Breast | IDC | 3.29e-03 | 1.32e-01 | 0.21 |
1477 | CSTF1 | GSM4909317 | Human | Breast | IDC | 2.50e-26 | 6.26e-01 | 0.1355 |
1477 | CSTF1 | GSM4909318 | Human | Breast | IDC | 5.96e-09 | 8.12e-01 | 0.2031 |
1477 | CSTF1 | DCIS2 | Human | Breast | DCIS | 8.35e-16 | 3.27e-02 | 0.0085 |
1477 | CSTF1 | LZE4T | Human | Esophagus | ESCC | 1.36e-10 | 2.02e-01 | 0.0811 |
1477 | CSTF1 | LZE7T | Human | Esophagus | ESCC | 1.41e-05 | 2.34e-01 | 0.0667 |
1477 | CSTF1 | LZE20T | Human | Esophagus | ESCC | 1.39e-07 | 1.26e-01 | 0.0662 |
1477 | CSTF1 | LZE24T | Human | Esophagus | ESCC | 2.58e-12 | 2.68e-01 | 0.0596 |
1477 | CSTF1 | P1T-E | Human | Esophagus | ESCC | 8.70e-03 | 1.91e-01 | 0.0875 |
1477 | CSTF1 | P2T-E | Human | Esophagus | ESCC | 9.82e-17 | 3.44e-01 | 0.1177 |
1477 | CSTF1 | P4T-E | Human | Esophagus | ESCC | 2.00e-09 | 1.73e-01 | 0.1323 |
1477 | CSTF1 | P5T-E | Human | Esophagus | ESCC | 8.29e-13 | 2.00e-01 | 0.1327 |
1477 | CSTF1 | P8T-E | Human | Esophagus | ESCC | 2.18e-06 | 1.17e-01 | 0.0889 |
1477 | CSTF1 | P9T-E | Human | Esophagus | ESCC | 1.69e-06 | 9.95e-02 | 0.1131 |
1477 | CSTF1 | P10T-E | Human | Esophagus | ESCC | 2.84e-24 | 4.27e-01 | 0.116 |
1477 | CSTF1 | P11T-E | Human | Esophagus | ESCC | 4.35e-17 | 3.26e-01 | 0.1426 |
1477 | CSTF1 | P12T-E | Human | Esophagus | ESCC | 1.57e-24 | 5.54e-01 | 0.1122 |
1477 | CSTF1 | P15T-E | Human | Esophagus | ESCC | 4.68e-22 | 3.80e-01 | 0.1149 |
1477 | CSTF1 | P16T-E | Human | Esophagus | ESCC | 6.57e-22 | 3.92e-01 | 0.1153 |
1477 | CSTF1 | P17T-E | Human | Esophagus | ESCC | 1.11e-04 | 2.94e-01 | 0.1278 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003112412 | Esophagus | ESCC | mRNA 3'-end processing | 47/8552 | 62/18723 | 1.29e-06 | 1.58e-05 | 47 |
GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
GO:00311241 | Liver | HCC | mRNA 3'-end processing | 50/7958 | 62/18723 | 8.44e-10 | 2.60e-08 | 50 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
GO:00311242 | Oral cavity | OSCC | mRNA 3'-end processing | 49/7305 | 62/18723 | 1.40e-10 | 4.14e-09 | 49 |
GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0301521 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
hsa0301531 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
hsa030158 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
hsa0301513 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CSTF1 | SNV | Missense_Mutation | novel | c.1190A>G | p.Asn397Ser | p.N397S | Q05048 | protein_coding | deleterious(0.04) | probably_damaging(0.992) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CSTF1 | SNV | Missense_Mutation | novel | c.1285A>G | p.Thr429Ala | p.T429A | Q05048 | protein_coding | tolerated(0.58) | benign(0.05) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CSTF1 | SNV | Missense_Mutation | novel | c.500N>A | p.Arg167Gln | p.R167Q | Q05048 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
CSTF1 | SNV | Missense_Mutation | c.1054N>T | p.Arg352Cys | p.R352C | Q05048 | protein_coding | deleterious(0.01) | benign(0.18) | TCGA-4R-AA8I-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CSTF1 | SNV | Missense_Mutation | c.346T>C | p.Tyr116His | p.Y116H | Q05048 | protein_coding | deleterious(0) | possibly_damaging(0.69) | TCGA-55-8094-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
CSTF1 | SNV | Missense_Mutation | c.286N>T | p.Ala96Ser | p.A96S | Q05048 | protein_coding | tolerated(0.19) | benign(0.255) | TCGA-86-8358-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
CSTF1 | SNV | Missense_Mutation | novel | c.752G>T | p.Cys251Phe | p.C251F | Q05048 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-95-A4VN-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CSTF1 | SNV | Missense_Mutation | novel | c.898N>G | p.Phe300Val | p.F300V | Q05048 | protein_coding | deleterious(0) | benign(0.02) | TCGA-NJ-A4YQ-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSTF1 | SNV | Missense_Mutation | novel | c.211N>T | p.Arg71Cys | p.R71C | Q05048 | protein_coding | tolerated(0.05) | benign(0.348) | TCGA-43-A56U-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CSTF1 | SNV | Missense_Mutation | novel | c.868N>C | p.Asp290His | p.D290H | Q05048 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-LA-A446-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |